Evidence map›Paper›PMID 27941020›Full record

Trial reportEuropean heart journal2017

Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.

Josep Brugada, Peter Paul Delnoy, Johannes Brachmann, Dwight Reynolds, Luigi Padeletti, Georg Noelker, Charan Kantipudi, José Manuel Rubin Lopez, Wolfgang Dichtl, Alberto Borri-Brunetto and 4 more

Registry-linked trialOpen access · bronzeAbstract readEquivalence TrialMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01534234 (Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01534234 phase3unknown statusnot on this map

Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D

TypeinterventionalSponsorMicroPort CRMRan2012 to 2019Enrolled1,039ConditionsHeart Failure NYHA Class III and Ambulatory IVArmsPARADYM RF SONR
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Conduction system pacing vs. biventricular pacing for cardiac resynchronization: the CSP-SYNC randomized single centre study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Progress in Cardiac Resynchronisation Therapy and Optimisation.Journal of cardiovascular development and disease · 2023
    Review
  11. Article
  12. Article
  13. Visualization of the SyncAVJournal of clinical medicine · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Inefficient diastolic filling in dual-chamber pacemaker recipients: impact of atrio-ventricular interval shortening (AVI-SHORT study).Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2023
    Article
  18. Article
  19. Review
  20. Determinants of Response to Cardiac Resynchronization Therapy.The Journal of innovations in cardiac rhythm management · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 6 countries.

Josep BrugadaCardiovascular Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Peter Paul DelnoyIsala klinieken Zwolle, Zwolle, The Netherlands.
Johannes BrachmannCoburg Hospital, Coburg, Germany.
Dwight ReynoldsUniversity of Oklahoma, Oklahoma City, OK, USA.
Luigi PadelettiUniversity of Florence, Italy and IRCCS Multimedica, Milan, Italy.
Georg NoelkerHerz- und Diabeteszentrum, Bad Oeynhausen, Germany.
Charan KantipudiPiedmont Heart Institute, Atlanta, GA, USA.
José Manuel Rubin LopezHospital Universitario Central de Asturias, Oviedo, Spain.
Wolfgang DichtlDepartment of Internal Medicine III, Innsbruck Medical University, Innsbruck, Austria.
Alberto Borri-BrunettoLivaNova Cardiac Rhythm Management, Saluggia, Italy.
Luc VerheesLivaNova, Clamart, France.
Philippe RitterUniversity Hospital of Bordeaux, Pessac, France.
Jagmeet P SinghMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
RESPOND CRT Investigators
Heart and Diabetes Center North Rhine-Westphalia · DEHospital Universitario Central de Asturias · ESInnsbruck Medical University · ATKlinikum Coburg · DELivaNova (France) · FRLivaNova (Italy) · ITMassachusetts General Hospital · USMultiMedica · ITPiedmont Atlanta Hospital · USUniversitat de Barcelona · ESUniversité de Bordeaux · FRUniversity of Oklahoma · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsAlthough cardiac resynchronization therapy (CRT) is effective in patients with systolic heart failure (HF) and a wide QRS interval, a substantial proportion of patients remain non-responsive. The SonR contractility sensor embedded in the right atrial lead enables individualized automatic optimization of the atrioventricular (AV) and interventricular (VV) timings. The RESPOND-CRT study investigated the safety and efficacy of the contractility sensor system in HF patients undergoing CRT. METHODS AND

resultsRESPOND-CRT was a prospective, randomized, double-blinded, multicentre, non-inferiority trial. Patients were randomized (2:1, respectively) to receive weekly, automatic CRT optimization with SonR vs. an Echo-guided optimization of AV and VV timings. The primary efficacy endpoint was the rate of clinical responders (patients alive, without adjudicated HF-related events, with improvement in New York Heart Association class or quality of life), at 12 months. The study randomized 998 patients. Responder rates were 75.0% in the SonR arm and 70.4% in the Echo arm (mean difference, 4.6%; 95% CI, -1.4% to 10.6%; P < 0.001 for non-inferiority margin -10.0%) (Table 2). At an overall mean follow-up of 548 ± 190 days SonR was associated with a 35% risk reduction in HF hospitalization (hazard ratio, 0.65; 95% CI, 0.46-0.92; log-rank P = 0.01).

conclusionAutomatic AV and VV optimization using the contractility sensor was safe and as effective as Echo-guided AV and VV optimization in increasing response to CRT. CLINICALTRIALS.GOV NUMBER: NCT01534234.

Indexed as

Cardiac Resynchronization Therapy DevicesAgedCardiac Resynchronization TherapyDouble-Blind MethodEquipment DesignFemaleFollow-Up StudiesHeart Failure, SystolicHumansMaleMyocardial ContractionProspective StudiesStroke VolumeTreatment OutcomeAdaptive CRTAV and VV optimizationCardiac contractilityCRT optimizationHF hospitalizationRESPONDSonR

Identifiers

PMID27941020
PMCPMC5353752
OpenAlexW2560695760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.